Drugs / LY03021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07371065 | Oct 2025 → Apr 2026 overdue | major depressive disorder | Luye Pharma Group Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371065 ↗ |
| Route | Oral | “Orally only once” NCT07371065 ↗ |